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SUMMARY – Prostate cancer represents a signifi cant public health burden in Croatia, as well as in 
other developed countries. Th e aim of this paper was to present the current epidemiological situation in 
Croatia in comparison to other similar countries, using basic indicators such as incidence, mortality, 
prevalence and survival, and to discuss future possibilities in this fi eld. Th e incidence of prostate cancer 
in Croatia has been rapidly increasing since the mid-nineties; recent data indicates that the trend is 
levelling off . Mortality data show constant increase since the 1960s, but mortality trends seem to be 
stabilizing in the recent period; however, Croatia is still in the top ten countries regarding prostate cancer 
mortality in Europe. Five-year prevalence in 2012 was estimated at 7,592 cases (426.7/100,000), ranking 
Croatia in the middle of European countries in the GLOBOCAN 2012 database. According to the 
CONCORD-2 study, fi ve-year net survival in Croatia in the 2005-2009 period was 75.1%, which is 
lower than in similar European countries. Th e epidemiological pattern of prostate cancer in Croatia 
 indicates a relatively low incidence, with signifi cant room for improvement in mortality and survival data. 
Given the recent discussions regarding prostate cancer screening modalities, a debate is warranted and 
should be encouraged regarding the role of PSA testing in Croatia.
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Introduction
Prostate cancer is the second most common cancer 
in men worldwide and the fi fth cause of cancer death1. 
Epidemiological indicators of the disease have changed 
immensely in the last couple of decades with the intro-
duction of PSA testing and improvements in treat-
ment. Th e disease poses a signifi cant health and fi nan-
cial burden, especially in more developed countries, so 
it is important to explore epidemiological indicators 
and trends.
Risk factors for prostate cancer include, most im-
portantly, older age, as well as heredity and ethnic ori-
gin2. A variety of other possible risk factors has been 
discussed, including, but not limited to, nutrition, oc-
cupational exposure and sexual behaviour. Th ere are no 
primary prevention programmes for prostate cancer; 
the role of PSA testing in population-based control of 
prostate cancer has been a matter of fi erce debate over 
the recent years3, with recent studies emphasizing the 
possibility of a tailored limited screening programme 
in a narrow age-group and including active surveil-
lance for men with low-risk tumours4.
Th e aim of this paper was to summarize the current 
epidemiological situation regarding prostate cancer in 
Croatia using available data and the implications of 
those data for future actions in prostate cancer control, 
with a focus on prostate cancer screening. Emphasis 
was placed on four main indicators of epidemiological 
situation regarding cancer in a particular country (in-
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cidence, mortality, survival and prevalence) and we 
aimed to present the latest available data, the relative 
position of Croatia in comparison to other similar 
countries and trends over time (before and after the 
wider introduction of PSA testing in our country).
Incidence of prostate cancer
According to estimates for 2012, there were more 
than a million (1,094,916; ASR=30.6/100,000) newly 
diagnosed cases of prostate cancer worldwide, and 
307,481 deaths (ASR=7.8/100,000)1. Prostate cancer 
incidence shows substantial geographic diff erences, 
more than 25-fold variations between countries with 
the highest rates (such as France and Norway) and 
those with the lowest rates (Uzbekistan, Bangladesh, 
Nepal, Bhutan). Generally, more developed countries 
have higher incidence, and the rise in incidence rates 
coincides with the implementation of PSA testing in 
these countries. Only 30% of prostate cancer cases 
worldwide are diagnosed in less developed regions.
Incidence pattern in Europe also corresponds to 
the level of development – age-standardized incidence 
rates are higher in Western (ASR=85.8/100 000) and 
Northern Europe (ASR=85/100 000), and noticeably 
lower in Southern (ASR=58.6/100 000) and Central 
and Eastern Europe (ASR=31.3/100 000)5.
Compared to GLOBOCAN 2012 estimates for 
other European countries, Croatia has an intermediate 
incidence rate of prostate cancer5. With age-standard-
ized rate (ASR) of 46.2/100 000, it is ranked 26th of 
40 European countries (Fig. 1). Th e highest ASR of 
129.7/100 000 was found in Norway and the lowest of 
15.8/100 000 in Albania. With regard to mortality 
data, Croatia is ranked eighth, with ASR of 
15.0/100 000. Th e highest rate of 21.4/100 000 was 
found in Lithuania, and the lowest of 7.8/100 000 in 
Malta (Fig. 1).
Virtually all European and other developed coun-
tries have experienced an increase in prostate cancer 
incidence6. Th e most prominent increase in the US oc-
curred in the early 1990s, reaching its peak in this pe-
riod as a result of the introduction of a larger-scale 
PSA testing7. Similar increases are described in some 
European countries; a publication by Center et al.6 dis-
played that the average annual percent change in the 
most recent 10-year period was signifi cantly increas-
ing in 80% (32 out of 40) of investigated countries, 
with changes such as +8.2% in Denmark, +8.1% in 
Ireland, +4.3% in Norway and +16.4% in Lithuania. In 
Croatia, prostate cancer incidence in this 10-year pe-
riod (1998-2007) increased by 8.5%; however, the be-
ginning of this period directly corresponds to a wider 
introduction of PSA testing in Croatia8.
Fig. 1. Estimates of age standardized (ASR-W) rates of incidence and mortality for prostate cancer in 2012, 
according to GLOBOCAN 2012 (5)
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When investigating a longer period of time, as was 
done in a recent publication with incidence trends in 
Croatia ranging back to 19689, it is clear that until the 
introduction of PSA testing the trends were increasing 
modestly (APC of +1.4% in 1982-1997 period, 95%CI 
0.7 to 2.1), followed by a steep increase in 1997-2002 
(APC +11.5%, 95% CI 7.5 to 15.7), a moderate in-
crease in the 2002-2009 period (APC +3.5%, 95% CI 
1.9 to 5.1) and without signifi cant change in trend in 
the 2009-2013 period (APC -2.0%, 95% CI -4.6 to 
0.5) (Fig. 2). Th is analysis needs to be prolonged with 
more recent data in order to gauge the magnitude of 
changes in recent years and to estimate if the incidence 
of prostate cancer in Croatia has indeed, somewhat 
unexpectedly, reached its plateau.
Th e most recent available published data for prostate 
cancer incidence in Croatia from the Croatian National 
Cancer Registry10 show that there were 1708 new cases 
of prostate cancer in Croatia in 2014; the crude rate was 
82.7/100.000, the age-standardized rate (European 
Standard Population 1976) 64.8/100.000, and the cu-
mulative incidence rate (0-74 years) was 5.5%.
Prostate cancer mortality
Prostate cancer mortality rates and trends in Europe 
also diff er according to regions, but diff erences are much 
less pronounced than those in incidence. In countries 
that were EU members before 2004 (which is some-
times used as a proxy measure for more developed coun-
tries), the standardized death rate (SDR) decreased 
from 27.3/100,000 in 1992 to 19.1/100,000 in 2012 
(11). In the same 20-year period mortality increased in 
countries that became EU members after 2004, from 
SDR=18.04/100,000 to SDR=21.3/100,000. Accord-
ing to the same source, prostate cancer mortality in 
Croatia increased from 22.8/100,000 in 1992 to 
26.6/100.000 in 201211.
Recent analysis of trends in prostate cancer mortal-
ity in Croatia9 indicated that in the period from 1960-
2010, prostate cancer mortality was increasing with a 
statistically signifi cant annual percent change of +1.2% 
(95%CI 1.0 to 1.4); there was a joinpoint in 2010 and 
the trend in 2010-2014 period was statistically not sig-
nifi cant (APC -1.2%, 95% CI -5.5 to 3.4).
Th e data for 2014, available at EUROSTAT web-
page12, also indicate that Croatia is among top ten EU 
countries in prostate cancer mortality (Fig. 3), with 
the age-standardized mortality rate of 54.9/100,000 
and share of all deaths in men of 3.0 in 2014. Th e share 
of all deaths in men that are attributable to prosta-
te cancer ranged from 1.7% in Bulgaria to 5.6% in 
Sweden.
Fig. 2. Prostate cancer incidence (1968-2013) and mortality rate (1960-2014) trends 
in Croatia; adapted from (9)
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Th e latest available mortality data for Croatia show 
that there were 769 deaths resulting from prostate 
cancer in 2016, with the crude rate of 38.2/100.000.
Prostate cancer survival
Prostate cancer survival can also be infl uenced by 
early detection of the disease, which can artifi cially 
lengthen survival time (lead-time bias). Th e amount of 
PSA testing that is taking place in a country should 
always be taken into account when interpreting sur-
vival and trends in survival.
Recent data on prostate cancer survival from two 
major international studies show that survival in 
 Croatia is below the European average. For men diag-
nosed between 2000 and 2007, the EUROCARE-5 
study showed a 5-year relative survival of 71.2% in 
Croatia13, and the European average of 83.4%. the 
Fig. 3. Standardized mortality rates (ASR-E) for prostate cancer in EU countries, 
according to EUROSTAT (12)
Fig. 4. Five-year age-standardized net survival of prostate cancer in European countries, 
according to CONCORD-2 study (13)
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CONCORD-2 study14 showed a 75.1% 5-year net 
survival for men diagnosed with prostate cancer in 
the 2005-2009 period, which is an improvement 
from the data for the periods 2000-2004 (67.7%) and 
1995-1999 (61.4%); however, Croatia still has survi-
val that is below the average of European countries 
(Fig. 4).
Prostate cancer prevalence
Th e increasing number of prostate cancers being 
detected through higher uptake of PSA screening has 
repercussions not only on survival, but on the preva-
lence of prostate cancer as well. Th e latest estimates 
from the International Agency for Research on Can-
cer (GLOBOCAN 2012)5 indicate that the highest 
5-year prevalence (the number/rate of persons alive 
that were diagnosed in the last 5 years) in Europe was 
observed in Sweden, Norway and Switzerland, where 
around 1/100 of all men were diagnosed with prostate 
cancer in the past 5 years (Fig. 5). Th e lowest 5-year 
prevalence was observed in the Republic of Moldova, 
Albania and the Ukraine, where around 1 in 1000 men 
were diagnosed with prostate cancer in the past 5 years. 
Croatia is ranked in the middle, with the rate of 
426.7/100.000 (Figure 5).
Fig. 5. Estimates of 5-year prevalence of prostate cancer in European countries, 
according to (5)
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PSA testing in Croatia and screening possibilities
While the highly cited US Preventive Services 
Task Force (USPSTF) recommendations in 2012 ad-
vised against prostate cancer screening due to concerns 
that a signifi cant proportion of screening-detected 
cancers may be overdiagnosed and overtreated, the 
2017 draft of the recommendations suggested an indi-
vidualized decision-making about screening for pros-
tate cancer after a discussion with a clinician for men 
between the ages of 55-6915. Future studies and pilot 
projects in this fi eld are needed, while modelling and 
microsimulation studies suggest various possible ap-
proaches depending on the context in which the 
screening could be done3,15,16.
A recent position paper3 suggested that starting a 
pilot programme involving a limited age-group could 
be the next step in the control of prostate cancer, while 
future developments in active surveillance, stratifi ed 
screening strategies along with advances in biomarkers 
and risk prediction may further improve the cost-ef-
fectiveness by improving the benefi ts and harms ratio. 
Also, the recent re-analysis of PLCO (Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial) and 
ERSPC (European Randomized Study of Screening 
for Prostate Cancer) data via mean lead times indi-
cated that, contrary to previously published data, when 
diff erences in the settings and implementation of the 
trials are controlled for, both of these studies provide 
evidence in favour of prostate cancer mortality reduc-
tion with screening17.
Other approaches, such as the so-called “basal PSA 
testing”, should also be taken into account. According 
to the works of Vickers and Lilja18,19, by adopting the 
“basal PSA-testing” strategy in the late forties, we 
could identify the population at the highest risk of 
prostate cancer development in the following years. 
Such an approach, coupled with a less frequent use of 
PSA testing at older age, might be useful in the reduc-
tion of PSA overutilization and the introduction of 
more rational and effi  cient principles in the fi eld of 
early diagnosis of high-risk prostate cancer. Th e dog-
matic practice of regular annual PSA testing for every 
man over 50 that has been in practice in Croatia, re-
gardless of recent and previous PSA values, has not 
met the expectations regarding improvement in the 
public health burden of prostate cancer.
In Croatia, PSA testing was widely introduced in 
the late 1990s and is currently applied as a mode of 
opportunistic screening in men aged 50 and over, de-
fi ned as individual case fi ndings initiated by the pa-
tient and/or his physician. A debate involving all rele-
vant stakeholders in Croatia on the benefi ts and harms 
of implementing/starting a possible diff erent prostate 
cancer screening programme should be initiated, with 
relevant national organisations and professional soci-
eties and committees leading the way towards the im-
plementation of the best possible scenario in the Croa-
tian setting.
Summary
Croatia is a country with an intermediate incidence 
of prostate cancer (in comparison to other European 
countries), but high prostate cancer mortality. Increas-
ing trends in incidence are expected, while there are no 
indications of decreasing trends in mortality which 
have been observed in other similar countries. Th e 
prevalence of prostate cancer in Croatia is average, 
while survival rates are below those of comparable Eu-
ropean countries.
Although there are no reliable data on the uptake of 
PSA testing in Croatia, this combination of basic epide-
miological parameters indicates that there is room for 
improvement regarding the overall prognosis and risks 
associated with prostate cancer in Croatian population. 
Th e combination of adopting new approaches in fi nd-
ing prostate cancer earlier in patients who would benefi t 
most from it and following European trends in the di-
agnostics and treatment of detected prostate cancer 
should be the way to move forward.
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Sažetak
EPIDEMIOLOGIJA RAKA PROSTATE U HRVATSKOJ - STANJE I PERSPEKTIVE
A. Reljić, P. Čukelj, I. Tomašković, B. Ružić i M. Šekerija
Rak prostate predstavlja značajan javnozdravstveni problem, kako u Hrvatskoj, tako i u drugim razvijenim zemljama. Cilj 
ovog članka je prikazati trenutnu epidemiološku situaciju povezanu s rakom prostate u Hrvatskoj u usporedbi s drugim slič-
nim zemljama korištenjem osnovnih epidemioloških indikatora kao što su incidencija, mortalitet, prevalencija i preživljenje, 
te razmotriti koje su daljnje mogućnosti za poboljšanje istih. Incidencija raka prostate u Hrvatskoj je u značajnom porastu od 
sredine 90-tih godina; posljednji dostupni podaci ukazuju da je taj trend potencijalno dosegao plato. Podaci o mortalitetu 
pokazuju stalan rast od 1960-ih, no iako vidimo stabilizaciju tog trenda u posljednjem periodu, Hrvatska je i dalje među 
prvih deset zemalja u Europi po smrtnosti od raka prostate. Procijenjeno je da je petogodišnja prevalencija u 2012. iznosila 
7.592 slučaja (426.7/100.000), što Hrvatsku smješta u sredinu europskih zemalja prema bazi podataka GLOBOCAN 2012. 
Petogodišnje preživljenje od raka prostate, prema istraživanju CONCORD-2, iznosi 75.1%, što je niže od preživljenja u 
nama sličnim europskim zemljama. Epidemiološki trendovi raka prostate u Hrvatskoj pokazuju relativno nisku incidenciju, 
dok prema podacima o mortalitetu i preživljenju vidimo da postoji mnogo mjesta za napredak. U svjetlu nedavnih diskusija 
o modelu ranog otkrivanja raka prostate, potrebno je održati i poticati raspravu o ulozi PSA testiranja u Hrvatskoj.
Ključne riječi: Rak prostate; Hrvatska; Incidencija; Mortalitet; Preživljenje; PSA testiranje
